How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

879 results for

Actinic Keratoses

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02120898 Recruitment Status : Completed First Posted : April 23, 2014 Last Update Posted : April 24, 2014

2014 Clinical Trials

102. Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks

Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2014 Clinical Trials

103. Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses

Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02251652 Recruitment Status : Completed First Posted

2014 Clinical Trials

104. Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities

Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02137785

2014 Clinical Trials

105. Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses

Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02289768 Recruitment Status : Completed First Posted : November 13, 2014

2014 Clinical Trials

106. A randomized clinical trial of photodynamic therapy with methylaminolevulinate versus 3% diclofenac plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. Full Text available with Trip Pro

A randomized clinical trial of photodynamic therapy with methylaminolevulinate versus 3% diclofenac plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. A gel containing diclofenac and hyaluronic acid (DHA) and photodynamic therapy with methyl aminolaevulinate (MAL-PDT) are widely used treatments for actinic keratoses (AKs).The aim of this single-centre, open-label, prospective, nonsponsored, randomized controlled clinical trial was to compare

2014 The British journal of dermatology Controlled trial quality: uncertain

107. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3,multicenter, randomized, double-blind, placebo-controlled studies. (Abstract)

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3,multicenter, randomized, double-blind, placebo-controlled studies. Imiquimod 3.75% and 2.5% creams were studied for the treatment of actinic keratosis (AK) of the full face or balding scalp, to determine comparable efficacy and tolerability to imiquimod 5% cream.In two identical multicenter, randomized, double-blind, placebo controlled studies. Adult subjects with 5 to 20 visible lesions, or palpable AKs in an area

2014 Journal of drugs in dermatology : JDD Controlled trial quality: predicted high

108. Cryotherapy is preferable to ablative CO<sub>2</sub> laser for the treatment of isolated actinic keratoses of the face and scalp: a randomised clinical trial. Full Text available with Trip Pro

Cryotherapy is preferable to ablative CO2 laser for the treatment of isolated actinic keratoses of the face and scalp: a randomised clinical trial. Actinic keratosis (AK) may progress to squamous cell carcinoma. In the case of normal or mildly photodamaged skin, lesion-directed treatments are considered valuable options despite poor published evidence of their therapeutic activity.The aim of this single-centre, open-label, prospective, nonsponsored, randomized, controlled clinical

2014 British Journal of Dermatology Controlled trial quality: uncertain

109. Prevalence and risk factors of actinic keratoses in Germany--analysis of multisource data. (Abstract)

Prevalence and risk factors of actinic keratoses in Germany--analysis of multisource data. In Europe, only few and inconsistent data on the prevalence and treatment of actinic keratoses (AK) are available.To determine the prevalence of AK in Germany, to identify potential predictors and to estimate the number of AK cases treated in dermatological practices.In a multiple-source approach, prevalence was assessed from whole-body examinations in a cohort of 90 800 employees and from nationwide

2014 Journal of the European Academy of Dermatology and Venereology

110. Prevalence of actinic keratosis in patients attending the dermatology outpatient clinic. Full Text available with Trip Pro

Prevalence of actinic keratosis in patients attending the dermatology outpatient clinic. Actinic keratoses (AKs) are precancerous epidermal lesions that develop on sensitive, frequently sun-exposed skin surfaces. There are very little data regarding AK prevalance. The aim of this study was to investigate the prevalence of AK and related conditions among patients in a dermatology outpatient clinic.Patients attending our dermatology outpatient clinic between January 1, 2015 and December 31, 2017

2019 Medicine

111. The more the better? An appraisal of combination therapies for actinic keratosis. Full Text available with Trip Pro

The more the better? An appraisal of combination therapies for actinic keratosis. Actinic keratoses (AK) are common precancerous lesions of the skin. Numerous interventions exist for the treatment of AK, including lesion- and field-directed approaches. In daily practice, different treatment modalities are often combined to maximize clearance rates. However, whether a combination therapy is preferable to monotherapy in terms of efficacy and safety has been subject of intense debate

2019 Journal of the European Academy of Dermatology and Venereology

112. The clinical course of actinic keratosis correlates with underlying molecular mechanisms. (Abstract)

The clinical course of actinic keratosis correlates with underlying molecular mechanisms. Actinic keratoses (AKs) are common premalignant skin lesions triggered by excessive ultraviolet exposure. The majority of AKs regress or persist, but some progress to squamous cell carcinomas. Biomarkers associated with their persistence, progression and regression have not been characterized.We performed skin biopsies in patients with extensive actinic damage to identify biomarkers that correlate (...) to apply sunscreens.At the molecular level, loss of E-cadherin and an increase in p53 are linked to the dynamic interplay between the persistence, progression and regression of AKs. What's already known about this topic? Actinic keratoses (AKs) are common dysplastic epidermal lesions that result from chronic and excessive ultraviolet exposure. Biomarkers associated with progression and regression of AK have not been characterized. What does this study add? Decreased E-cadherin and increased p53, Snail

2019 British Journal of Dermatology

113. Effective treatment of disseminated superficial actinic porokeratosis with chemical peels - customary treatment for a rare disease. (Abstract)

Effective treatment of disseminated superficial actinic porokeratosis with chemical peels - customary treatment for a rare disease. Disseminated superficial actinic porokeratosis (DSAP) is a rare dermatologic disorder of the epidermis. Often misdiagnosed as chronic UV-damage or actinic keratoses, patients are treated for years with different therapeutic options with little success. Current treatment options include imiquimod, ingenol mebutate, cryosurgery, photodynamic therapy and topical

2019 Journal of Dermatological Treatment

114. Efficacy of topical Imiquimod 3.75% in the treatment of Actinic Keratosis of the scalp in immunosuppressed patients: our case series. Full Text available with Trip Pro

Efficacy of topical Imiquimod 3.75% in the treatment of Actinic Keratosis of the scalp in immunosuppressed patients: our case series. Actinic keratoses (AK) represent common cutaneous lesions, appearing in "Field cancerization areas" and potentially evolving towards invasive neoplasm. Immunosuppressed patients frequently develop numerous and aggressive AKs.In this observational study, we report our experience with topical Imiquimod 3.75% as "Field-directed therapy" in a cohort

2019 Journal of Dermatological Treatment

115. Actinic Keratosis and Cutaneous Squamous Cell Carcinoma. Full Text available with Trip Pro

Actinic Keratosis and Cutaneous Squamous Cell Carcinoma. Cutaneous squamous cell carcinoma (cSCC) and its precursors, actinic keratoses (AK), are common. Physicians of multiple specialties are confronted with their treatment.This review is based on publications retrieved by a selective search in PubMed, as well as on the German guidelines on AK and cSCC, skin cancer prevention, and surgery with histologic guidance.Local treatments for AK include lesional cryotherapy, curettage, and laser

2019 Deutsches Arzteblatt international

116. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. Full Text available with Trip Pro

Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. Ingenol mebutate is the active agent (a macrocyclic diterpene ester) in the sap of the plant Euphorbia peplus. This herb has been used as a traditional remedy for several different skin lesions, including skin cancers.To assess 12-month recurrence rates and safety associated with ingenol mebutate gel treatment in patients who previously had achieved complete clearance of actinic keratoses.The treatment (...) area was observed for recurrence for 12 months after the original study. Patients were treated in an outpatient setting.Patients received ingenol mebutate gel, 0.015%, daily for 3 consecutive days for actinic keratoses on the face or scalp or ingenol mebutate gel, 0.05%, daily for 2 consecutive days for actinic keratoses on the trunk or extremities. Study participants had achieved complete clearance in a prespecified 25-cm2 area at day 57 of their original trial.Recurrence rates and safety were

2013 JAMA dermatology (Chicago, Ill.)

117. Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%

Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05% Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05% - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05% The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01892137 Recruitment Status : Completed First

2013 Clinical Trials

118. Treating Actinic Keratoses With Natural Daylight PDT: Comparing Two Light Sensitizers (ALA and MAL)

Treating Actinic Keratoses With Natural Daylight PDT: Comparing Two Light Sensitizers (ALA and MAL) Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) clinically, histopathologically and immunohistochemically. Condition or disease Intervention/treatment Phase Multiple Actinic Keratoses Drug: BF-200 ALA cream Drug: MAL cream Phase 4 Detailed Description: Actinic keratoses (AKs) are superficial premalignant skin lesions that can progress into an invasive or metastatic squamous cell carcinoma. AKs can be treated with photodynamic therapy (PDT), of which cure rate compares to cryo surgery with an excellent cosmesis. In PDT the AK lesions are first

2013 Clinical Trials

119. Fractional Laser-assisted Daylight Photodynamic Therapy Versus Daylight Photodynamic for Treatment of Actinic Keratoses

Fractional Laser-assisted Daylight Photodynamic Therapy Versus Daylight Photodynamic for Treatment of Actinic Keratoses Fractional Laser-assisted Daylight Photodynamic Therapy Versus Daylight Photodynamic for Treatment of Actinic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Fractional Laser-assisted Daylight Photodynamic Therapy Versus Daylight Photodynamic for Treatment of Actinic Keratoses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01898936 Recruitment Status : Completed First

2013 Clinical Trials

120. Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses

Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses (COMET2) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01821391 Recruitment Status : Completed First Posted : April 1, 2013 Last Update Posted : September 12, 2014 Sponsor: Galderma

2013 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>